Form 8-K - Current report:
SEC Accession No. 0001213900-23-001264
Filing Date
2023-01-06
Accepted
2023-01-06 11:28:33
Documents
14
Period of Report
2023-01-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea171341-8k_longeveron.htm   iXBRL 8-K 35261
2 PRESS RELEASE DATED JANUARY 6, 2023 ea171341ex99-1_longeveron.htm EX-99.1 17193
3 GRAPHIC ex99-1_001.jpg GRAPHIC 7653
  Complete submission text file 0001213900-23-001264.txt   244720

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lgvn-20230106.xsd EX-101.SCH 3233
5 XBRL LABEL FILE lgvn-20230106_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE lgvn-20230106_pre.xml EX-101.PRE 22363
8 EXTRACTED XBRL INSTANCE DOCUMENT ea171341-8k_longeveron_htm.xml XML 3714
Mailing Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136
Business Address 1951 NW 7TH AVENUE SUITE 520 MIAMI FL 33136 305-302-7158
Longeveron Inc. (Filer) CIK: 0001721484 (see all company filings)

EIN.: 472174146 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40060 | Film No.: 23514181
SIC: 2834 Pharmaceutical Preparations